Skip to main content
Erschienen in: World Journal of Surgery 7/2007

01.07.2007

The Influence of High Serum Testosterone Levels on the Long-term Prognosis in Male Patients Undergoing Hepatectomy for Early Stage Hepatocellular Carcinoma without Vascular Invasion

verfasst von: Min-Che Lin, Cheng-Chung Wu, Shao-Bin Cheng, Tse-Jia Liu, Fang-Ku P’eng

Erschienen in: World Journal of Surgery | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

The influence of high serum testosterone levels on the long-term prognosis in male patients undergoing hepatectomy for hepatocellular carcinoma (HCC) remains to be fully elucidated. The aim of the present study was to conduct a retrospective investigation of the impact of high serum testosterone levels on the risk of tumor recurrence and long-term prognosis in male patients undergoing hepatectomy for early stage HCC without vascular invasion.

Methods

Between August 1995 and March 1999, 42 male patients undergoing curative hepatectomy for HCC of tumor-node-metastasis (TNM) stages I and II without vascular invasion were enrolled in the study. Preoperative serum testosterone concentration was measured. The clinicopathological features, tumor recurrence rates, and 5-year disease-free and actuarial survival after hepatectomy were compared between the patients with serum testosterone levels in the upper half (group I, n = 21) and the patients in the lower half (group II, n = 21).

Results

The background and clinicopathological features did not differ significantly between groups I and group II. All survivors were followed up for more than 5 years. Until March 2005, patients in group I, with serum testosterone levels in the upper half, had a significantly higher percentage of 5-year tumor recurrence than group II, with lower testosterone levels (76.2% versus 28.6%; p < 0.005). The patients in group I also had a significantly inferior 5-year disease-free (p < 0.01) and actuarial (p < 0.05) survival rates than patients in group II.

Conclusions

Male patients with high serum testosterone levels undergoing hepatectomy for early stage HCC without vascular invasion have significantly higher 5-year tumor recurrence rates and an inferior long-term prognosis than patients with low testosterone levels. These findings signal a strategy of adjuvant anti-androgen treatment selectively targeted for the male patients with high serum testosterone levels after hepatectomy for early stage HCC without vascular invasion to achieve better long-term outcome.
Literatur
1.
Zurück zum Zitat Peters RI. (1976) Pathology of hepatocellular carcinoma. In Okuda K, Peters RI, editors, Hepatocellular Carcinoma, New York, John Wiley & Sons:107–168 Peters RI. (1976) Pathology of hepatocellular carcinoma. In Okuda K, Peters RI, editors, Hepatocellular Carcinoma, New York, John Wiley & Sons:107–168
2.
Zurück zum Zitat Editorial. (1987) Hepatocellular cancer: differences between high and low incidence regions. Lancet 2:1183–1184 Editorial. (1987) Hepatocellular cancer: differences between high and low incidence regions. Lancet 2:1183–1184
3.
Zurück zum Zitat Yu MW, Tsai SF, Hsu KH, et al. (1988) Epidemiological characteristics of malignant neoplasm in Taiwan. II. Liver cancer. J Natl Public Health Assoc 8:125–138 Yu MW, Tsai SF, Hsu KH, et al. (1988) Epidemiological characteristics of malignant neoplasm in Taiwan. II. Liver cancer. J Natl Public Health Assoc 8:125–138
4.
Zurück zum Zitat Yu MW, Chen CJ. (1993) Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 53:790–794PubMed Yu MW, Chen CJ. (1993) Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 53:790–794PubMed
5.
Zurück zum Zitat Yu MW, Cheng SW, Lin MW, et al. (2000) Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 92:2023–2028PubMedCrossRef Yu MW, Cheng SW, Lin MW, et al. (2000) Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 92:2023–2028PubMedCrossRef
6.
Zurück zum Zitat Yu MW, Yang YC, Yang SY, et al. (2001) Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 93:1644–1651PubMedCrossRef Yu MW, Yang YC, Yang SY, et al. (2001) Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 93:1644–1651PubMedCrossRef
7.
Zurück zum Zitat Tanaka K, Sakai H, Hashizume M, et al. (2000) Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 60:5106–5110PubMed Tanaka K, Sakai H, Hashizume M, et al. (2000) Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 60:5106–5110PubMed
8.
Zurück zum Zitat Sobin LH, Wittekind CH. (2002) International Union Against Cancer. TNM Classification of Malignant Tumors, 6th Edition, John Wiley, New York Sobin LH, Wittekind CH. (2002) International Union Against Cancer. TNM Classification of Malignant Tumors, 6th Edition, John Wiley, New York
9.
Zurück zum Zitat Couinaud C. (1989) Surgical Anatomy of the Liver, Revisited. C. Couinaud, Paris Couinaud C. (1989) Surgical Anatomy of the Liver, Revisited. C. Couinaud, Paris
10.
Zurück zum Zitat Wu CC, Ho WL, Yeh DC, et al. (1996) Hepatic resection of hepatocellular carcinoma in cirrhotic livers: is it unjustified in impaired liver function? Surgery 120:34–39PubMedCrossRef Wu CC, Ho WL, Yeh DC, et al. (1996) Hepatic resection of hepatocellular carcinoma in cirrhotic livers: is it unjustified in impaired liver function? Surgery 120:34–39PubMedCrossRef
11.
Zurück zum Zitat Wu CC, Yeh DC, Lin MC, et al. (2001) Improving operative safety for cirrhotic liver resection. Br J Surg 88:210–215PubMedCrossRef Wu CC, Yeh DC, Lin MC, et al. (2001) Improving operative safety for cirrhotic liver resection. Br J Surg 88:210–215PubMedCrossRef
12.
Zurück zum Zitat Wu CC, Hwang CR, Liu TJ et al. (1996) Effects and limitations of prolonged ischemia for hepatic resection of the cirrhotic liver. Br J Surg 83:121–124PubMedCrossRef Wu CC, Hwang CR, Liu TJ et al. (1996) Effects and limitations of prolonged ischemia for hepatic resection of the cirrhotic liver. Br J Surg 83:121–124PubMedCrossRef
13.
Zurück zum Zitat Wu CC, Yeh DC, Ho WM, et al. (2002) Occlusion of hepatic blood inflow for complex central liver resections in cirrhotic patients. Arch Surg 137:1369–1376PubMedCrossRef Wu CC, Yeh DC, Ho WM, et al. (2002) Occlusion of hepatic blood inflow for complex central liver resections in cirrhotic patients. Arch Surg 137:1369–1376PubMedCrossRef
14.
Zurück zum Zitat Nagasue N, Galizia G, Yukaya H, et al. (1989) Better survival in women than in men after radical resection of hepatocellular carcinoma. Hepatogastroenterology 36:379–383PubMed Nagasue N, Galizia G, Yukaya H, et al. (1989) Better survival in women than in men after radical resection of hepatocellular carcinoma. Hepatogastroenterology 36:379–383PubMed
15.
Zurück zum Zitat Lee CC, Chau GY, Lui WY, et al. (2000) Better post-resectional survival in female cirrhotic patients with hepatocellular carcinoma. Hepatogastroenterology 47:446–449PubMed Lee CC, Chau GY, Lui WY, et al. (2000) Better post-resectional survival in female cirrhotic patients with hepatocellular carcinoma. Hepatogastroenterology 47:446–449PubMed
16.
Zurück zum Zitat Lam CM, Yong JL, Chan AO, et al. (2005) Better survival in female patients with hepatocellular carcinoma: oral contraceptive pills related? J Clin Gastroenterol 39:533–539PubMedCrossRef Lam CM, Yong JL, Chan AO, et al. (2005) Better survival in female patients with hepatocellular carcinoma: oral contraceptive pills related? J Clin Gastroenterol 39:533–539PubMedCrossRef
17.
Zurück zum Zitat Morris HP, Firminger HI. (1960) Influence of sex and sex hormones on development of hepatomas and other hepatic lesions in strain AX C rats ingesting 2-diacetylaminofluorene. J Natl Cancer Inst 16:927–949 Morris HP, Firminger HI. (1960) Influence of sex and sex hormones on development of hepatomas and other hepatic lesions in strain AX C rats ingesting 2-diacetylaminofluorene. J Natl Cancer Inst 16:927–949
18.
Zurück zum Zitat Firminger HI, Reuber MD. (1961) Influence of adrenocortical, androgenic, and anabolic hormones on the development of carcinoma and cirrhosis of the liver in A x C rats fed N-2-fluorenyldicetamide. J Natl Cancer Inst 27:559–595PubMed Firminger HI, Reuber MD. (1961) Influence of adrenocortical, androgenic, and anabolic hormones on the development of carcinoma and cirrhosis of the liver in A x C rats fed N-2-fluorenyldicetamide. J Natl Cancer Inst 27:559–595PubMed
19.
Zurück zum Zitat Toh YC. (1981) Effect of neonatal castration on liver tumor induction by N-2-fluorenylacetamide in suckling BALB/c mice. Carcinogenesis 2:1219–1221PubMedCrossRef Toh YC. (1981) Effect of neonatal castration on liver tumor induction by N-2-fluorenylacetamide in suckling BALB/c mice. Carcinogenesis 2:1219–1221PubMedCrossRef
20.
Zurück zum Zitat Moore MR, Drinkwater NR, Miller EC, et al. (1981) Quantitative analysis of the time-dependent development of glucose-6-phosphatase-deficient foci in the livers of mice treated neonatally with diethylnitrosamine. Cancer Res 41:1585–1593PubMed Moore MR, Drinkwater NR, Miller EC, et al. (1981) Quantitative analysis of the time-dependent development of glucose-6-phosphatase-deficient foci in the livers of mice treated neonatally with diethylnitrosamine. Cancer Res 41:1585–1593PubMed
21.
Zurück zum Zitat Matsuura B, Taniguchi Y, Ohta Y. (1994) Effect of antiandrogen treatment on chemical hepatocarcinogenesis in rats. J Hepatol 21:187–193PubMedCrossRef Matsuura B, Taniguchi Y, Ohta Y. (1994) Effect of antiandrogen treatment on chemical hepatocarcinogenesis in rats. J Hepatol 21:187–193PubMedCrossRef
22.
Zurück zum Zitat Johnson FL, Lerner KG, Siegel M, et al. (1972) Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 2:1273–1276PubMedCrossRef Johnson FL, Lerner KG, Siegel M, et al. (1972) Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 2:1273–1276PubMedCrossRef
23.
24.
Zurück zum Zitat Mokrohisky ST, Ambruso DR, Hathaway WE. (1977) Fulminant hepatic neoplasia after androgen therapy. N Engl J Med 296:1411–1412PubMedCrossRef Mokrohisky ST, Ambruso DR, Hathaway WE. (1977) Fulminant hepatic neoplasia after androgen therapy. N Engl J Med 296:1411–1412PubMedCrossRef
25.
Zurück zum Zitat Johnson PJ. (1984) Sex hormones and the liver. Clin Sci (Lond) 66:369–376 Johnson PJ. (1984) Sex hormones and the liver. Clin Sci (Lond) 66:369–376
26.
Zurück zum Zitat Ho WL, Wu CC, Yeh -D-C, et al. (2002) Roles of the glucocorticoid receptor in resectable hepatocellular carcinoma. Surgery 131:19–25PubMedCrossRef Ho WL, Wu CC, Yeh -D-C, et al. (2002) Roles of the glucocorticoid receptor in resectable hepatocellular carcinoma. Surgery 131:19–25PubMedCrossRef
27.
Zurück zum Zitat Eagon PK, Porter LE, Francavilla A, et al. (1985) Estrogen and androgen receptors in liver: their role in liver disease and regeneration. Semin Liver Dis 5:59–69PubMedCrossRef Eagon PK, Porter LE, Francavilla A, et al. (1985) Estrogen and androgen receptors in liver: their role in liver disease and regeneration. Semin Liver Dis 5:59–69PubMedCrossRef
28.
Zurück zum Zitat Yu L, Nagasue N, Makino Y, et al. (1995) Effect of androgens and their manipulation on cell growth and androgen receptor (AR) levels in AR-positive and -negative human hepatocellular carcinomas. J Hepatol 22:295–302PubMedCrossRef Yu L, Nagasue N, Makino Y, et al. (1995) Effect of androgens and their manipulation on cell growth and androgen receptor (AR) levels in AR-positive and -negative human hepatocellular carcinomas. J Hepatol 22:295–302PubMedCrossRef
29.
Zurück zum Zitat Nagasue N, Ito A, Yukaya H, et al. (1985) Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology 89:643–647PubMed Nagasue N, Ito A, Yukaya H, et al. (1985) Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology 89:643–647PubMed
30.
Zurück zum Zitat Nagasue N, Chang YC, Hayashi T, et al. (1989) Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resection. Ann Surg 209:424–427PubMedCrossRef Nagasue N, Chang YC, Hayashi T, et al. (1989) Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resection. Ann Surg 209:424–427PubMedCrossRef
31.
Zurück zum Zitat Nagasue N, Yu L, Yukaya H, et al. (1995) Androgen and estrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. Br J Surg 82:542–547PubMedCrossRef Nagasue N, Yu L, Yukaya H, et al. (1995) Androgen and estrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. Br J Surg 82:542–547PubMedCrossRef
32.
Zurück zum Zitat Imamura H, Matsuyama Y, Tanaka E, et al. (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol 38:200–207PubMedCrossRef Imamura H, Matsuyama Y, Tanaka E, et al. (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol 38:200–207PubMedCrossRef
33.
Zurück zum Zitat Shah SA, Greig PD, Gallinger S, et al. (2006) Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg 202:275–283PubMedCrossRef Shah SA, Greig PD, Gallinger S, et al. (2006) Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg 202:275–283PubMedCrossRef
34.
Zurück zum Zitat Sakon M, Umeshita K, Nagano H, et al. (2000) Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg 135:1456–1459PubMedCrossRef Sakon M, Umeshita K, Nagano H, et al. (2000) Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by disease-free survival curves. Arch Surg 135:1456–1459PubMedCrossRef
35.
Zurück zum Zitat Ohnishi S, Murakami T, Moriyama T, et al. (1986) Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology 6:440–443PubMedCrossRef Ohnishi S, Murakami T, Moriyama T, et al. (1986) Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology 6:440–443PubMedCrossRef
36.
Zurück zum Zitat Boix L, Castells A, Bruix J, et al. (1995) Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. J Hepatol 22:616–622PubMedCrossRef Boix L, Castells A, Bruix J, et al. (1995) Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. J Hepatol 22:616–622PubMedCrossRef
37.
Zurück zum Zitat Forbes A, Wilkinson ML, Iqbal MJ, et al. (1987) Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone. Eur J Cancer Clin Oncol 23:1659–1664PubMedCrossRef Forbes A, Wilkinson ML, Iqbal MJ, et al. (1987) Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone. Eur J Cancer Clin Oncol 23:1659–1664PubMedCrossRef
38.
Zurück zum Zitat Gupta S, Korula J. (1988) Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma. J Clin Gastroenterol 10:651–654PubMedCrossRef Gupta S, Korula J. (1988) Failure of ketoconazole as anti-androgen therapy in nonresectable primary hepatocellular carcinoma. J Clin Gastroenterol 10:651–654PubMedCrossRef
39.
Zurück zum Zitat Guechot J, Peigney N, Ballet F, et al. (1989) Effect of D-tryptophan-6-luteinizing hormone-releasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients with hepatocellular carcinoma. Hepatology 1989;10:346–348CrossRef Guechot J, Peigney N, Ballet F, et al. (1989) Effect of D-tryptophan-6-luteinizing hormone-releasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients with hepatocellular carcinoma. Hepatology 1989;10:346–348CrossRef
40.
Zurück zum Zitat Chao Y, Chan WK, Huang YS, et al. (1996) Phase II study of flutamide in the treatment of hepatocellular carcinoma. Cancer 77:635–639PubMedCrossRef Chao Y, Chan WK, Huang YS, et al. (1996) Phase II study of flutamide in the treatment of hepatocellular carcinoma. Cancer 77:635–639PubMedCrossRef
41.
Zurück zum Zitat Pignata S, Daniele B, Gallo C, et al. (1998) Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit? Eur J Cancer 34:25–32PubMedCrossRef Pignata S, Daniele B, Gallo C, et al. (1998) Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit? Eur J Cancer 34:25–32PubMedCrossRef
Metadaten
Titel
The Influence of High Serum Testosterone Levels on the Long-term Prognosis in Male Patients Undergoing Hepatectomy for Early Stage Hepatocellular Carcinoma without Vascular Invasion
verfasst von
Min-Che Lin
Cheng-Chung Wu
Shao-Bin Cheng
Tse-Jia Liu
Fang-Ku P’eng
Publikationsdatum
01.07.2007
Verlag
Springer-Verlag
Erschienen in
World Journal of Surgery / Ausgabe 7/2007
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-007-9094-3

Weitere Artikel der Ausgabe 7/2007

World Journal of Surgery 7/2007 Zur Ausgabe

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.